Article

Validation of the predictive ability for recurrence and the clinical utility of the 95-gene classifier (95GC) through an integrated analysis of five studies.

2025-04-21

Abstract excerpt

<title>Abstract</title> <p>Background In recent years, multigene assays have become indispensable tools for predicting the recurrence risk of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer and guiding adjuvant chemotherapy decisions. Curebest™ 95GC Breast (95GC), developed in 2011 as a domestically produced multigene assay for postoperative rec...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a7c05922-5236-5af5-a818-2a0029efa32b
DOI: 10.21203/rs.3.rs-6282865/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Validation of the predictive ability for recurrence and the clinical utility of the 95-gene classifier (95GC) through an integrated analysis of five studies.DOI 10.21203/rs.3.rs-6282865/v1Read

Evaluation of 95-Gene Classifier of Formalin-Fixed Paraffin-Embedded Tissues in ER-Positive, HER2-Negative, and Node-Negative Breast CancerSemantic proximity Read

A 95-gene Signature Stratifies Recurrence Risk of Invasive Disease in ER-positive, HER2-negative, Node-negative Breast Cancer With Intermediate 21-gene Signature Recurrence ScoresSemantic proximity Read

PreciseBreast is prognostic for breast cancer recurrence in a 21-gene assay managed cohortSemantic proximity Read

Integration of gene expression profiling and mutation analysis via RNA sequencing: transitioning the 95-gene classifier to a next-generation platform in early-stage HR+/HER2- breast cancer.Semantic proximity Read

Prospective Validation of a 21-Gene Expression Assay in Breast CancerSemantic proximity Read

Comparative Evaluation of a 28-Gene versus 70-Gene Panel for Recurrence Risk Prediction in Early-Stage HR-Positive/HER2-Negative Breast Cancer in Chinese WomenSemantic proximity Read

High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancerSemantic proximity Read

Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score.Semantic proximity Read

Validation of a Clinical-Genomic Model for Patients With Early-Stage Breast Cancer Enrolled in a Taiwanese Multicenter StudySemantic proximity Read

The Early-Stage Triple-Negative Breast Cancer Landscape Derives a Novel Prognostic Signature and Therapeutic TargetSemantic proximity Read

Prediction of the 70-gene signature (MammaPrint) high versus low risk by nomograms among axillary lymph node positive (LN+) and negative (LN-) Chinese breast cancer patients, a retrospective studySemantic proximity Read

Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer RecurrenceSemantic proximity Read